Morning Briefing
Summaries of health policy coverage from major news organizations
Sen. Grassley Postpones Hearing On EpiPen Rebates To Government Programs
The Associated Press: Grassley Mulls Subpoenas For Mylan, DOJ Over EpiPen
The chairman of the Senate Judiciary Committee said Wednesday he is considering a subpoena or another method of compelling testimony from the pharmaceutical company Mylan, the Justice Department and the federal Centers for Medicare and Medicaid Services. All three parties have refused to attend a committee hearing next week. Sen. Charles Grassley, R-Iowa, said in a statement that he is postponing the Nov. 30 hearing on a possible settlement between Mylan and the Justice Department over Mylan's life-saving EpiPen. Grassley said that because of the parties' refusal to participate, "we must now consider compelling their participation." (Jalonick, 11/23)
Reuters: Senate Panel Postpones Mylan Hearing
Mylan has come under fire for raising the price of a pair of EpiPens to $600 from $100 in 2008 and listing it with Medicaid as a generic product even though it is listed with the U.S. Food and Drug Administration as a branded product. Companies pay smaller rebates to Medicaid for generics. (Bartz, 11/24)
